Why the study?
Hypertension is present in >80% of maintenance hemodialysis patients and has a unique multifactorial pathophysiology, warranting a review of evidence on its definition, diagnosis, and treatment.
This AHA scientific statement provides a comprehensive review of the evidence and future opportunities for managing hypertension in patients on maintenance hemodialysis.
High prevalence necessitates targeted BP management in hemodialysis; leaves open optimal strategies amid mixed evidence.
Nearly 500 000 individuals are treated with maintenance hemodialysis for kidney failure in the United States, and roughly half will die of cardiovascular causes. Hypertension, an important and modifiable risk factor for cardiovascular disease, is observed in >80% of patients treated with maintenance hemodialysis. The pathophysiology of hypertension in patients treated with maintenance hemodialysis is multifactorial and differs from that seen in other patient populations. Factors that contribute to hypertension in patients treated with hemodialysis include volume overload, arterial stiffness, enhanced activity of the sympathetic nervous and renin-angiotensin-aldosterone systems, endothelial dysfunction, and use of erythropoietin-stimulating agents. This scientific statement reviews the current evidence on defining, diagnosing, and treating hypertension in patients treated with maintenance hemodialysis and highlights opportunities for future investigation, including studies on blood pressure targets and treatment strategies.
No takes yet. Share an insight, caveat, or question.
Bansal et al. (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: